680,000 patients in the USA alone suffer from End Stage Renal Disease and millions more around the world.
ESRD treatment now costs Medicare over $100 billion per year for dialysis treatments and related patient services.
Nearly 100,000 Americans are on the wait list for a kidney transplant. Average wait time is 3-7 years.
US Kidney Research Corporation (formerly Curion Research Corporation), is a Delaware
C-Corp founded in June, 2015. For over 5 years, US Kidney Research Corporation has been involved in R&D of the world’s first waterless renal replacement technology.
Unlike standard dialysis, our new technology does not require purified water, dialysate concentrate solutions, or a dialyzer. Imagine the advantages of having not to deal with dialysate solutions. For patients and technicians, whether in a home or clinical setting, it simplifies the entire blood purifying process. For providers, it eliminates the massive water purifying infrastructure, saving enormous overhead costs.
Initially, our technology will be used to develop a wearable artificial kidney. Ultimately, the same technology can be used in a standalone waterless renal therapy machine and implantable devices.
First in the world to create synthetic urine using a new blood purifying technology that involves filtration and ion transport processes similar to the native kidney. Animal studies performed at Noble Life Sciences using our latest prototype - Maryland
Award winner of KidneyX Redesign Dialysis Phase 1 contest sponsored in partnership by US Dept. of Health and Human Services and the American Society of Nephrology.
Invited as Guest speaker by International Federation for Artificial Organs (IFAO) to present at the American Society for Implantable Artificial Organs (ASAIO) Chicago conference in June 2020. We were invited again to speak in Washington DC in June 2021.
Science article recently published in Nature, the premier science journal in the world. Entitled: Simulating nephron ion transport function using activated wafer electrodeionization.
US Patent - Granted 2021 - Patent No. 1093318
PCT international patents are filed in many EPO member countries (Europe), as well as in China, India, Singapore, Japan, S. Korea, Australia, Canada and Mexico.
While developing our dialysis replacement technology, our primary research has led to other inventions:
1. We are developing a new anti-coagulant coating that can be used to keep medical devices, blood testing equipment, and catheters from clotting. One major benefit is this will eliminate the need for anti-coagulant during a treatment session.
2. We have developed a new method using our technology to regenerate peritoneal dialysis solution in PD patients. Our technology will significantly reduce the number of peritoneal solutions required by the industry.
Our revolutionary technology for purifying the blood of patients with end stage kidney disease has the potential to completely replace current dialysis procedures in an industry that has not changed its methodology in decades. In collaboration with advisers and research scientists from two major universities, US Kidney Research Corporation has made significant progress in achieving its goals.
It is our intention to bring this new technology to clinical practice and help all those suffering from end stage renal disease.
US Kidney Research Corporation has developed a unique technology that represents a fundamental paradigm shift in renal replacement therapy.